АНГИОГЕНЕЗ ПРИ ПРОЛИФЕРАТИВНОЙ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ: ПЕРСПЕКТИВЫ АНТИ-VEGF-ТЕРАПИИ (ОБЗОР ЛИТЕРАТУРЫ)

Oftal mokhirurgiya

В. В. Черных¹  Н. В. Тян²  В. В. Климонтов²  В. И. Коненков² 

[1] Новосибирский филиал ФГБУ «МНТК «Микрохирургия глаза» им. акад. С.Н. Федорова» Минздрава России;ФГБУ «НИИ клинической и экспериментальной лимфологии» СО РАМН

关键词: proliferative diabetic retinopathy;    neovascularization;    angiogenesis;    bevacizumab;    ranibizumab;    pegaptanib;    aflibercept;    пролиферативная диабетическая ретинопатия;    неоваскуляризация;    ангиогенез;    бевацизумаб;    ранибизумаб;    пегаптаниб;    афлиберцепт;   

DOI  :  10.25276/0235-4160-2013-4-111-115

学科分类：眼科学

来源: M H T K Mikrokhirurgiya Glaza

【 摘 要 】

VEGF-mediated angiogenesis is a key mechanism of pathologic retinal neovascularization in the proliferative diabetic retinopathy (PDR). Therefore, the anti-VEGF therapy can be considered as a perspective approach for the treatment of this complication. In patients with the PDR the combination of anti-VEGF agents with a panretinal photocoagulation prevents a decrease of visual acuity, a development of macular edema and, according to some data, enhances a neovascularization regression. In patients with vitreous hemorrhages the anti-VEGF agents injection before the vitrectomy reduces the incidence of recurrent hemorrhages in intra- and postoperative period. In eyes with PDR complicated with neovascular glaucoma the intravitreal bevacizumab injection leads to a regression of iris and anterior angle vascularization. Currently, the most frequent data exist in the use of bevacizumab, the effects of ranibizumab and pegaptanib are investigated in a lesser extent, researches of aflibercept have been initiated recently. Future studies are required to estimate the necessary duration and effectiveness predictors of anti-VEGF therapy, as well as the best combinations of anti-VEGF agents with other treatment modalities.

【 授权许可】

CC BY